Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Enliven Therapeutics (ELVN) Net Income towards Common Stockholders (2019 - 2026)

Enliven Therapeutics has reported Net Income towards Common Stockholders over the past 8 years, most recently at -$23.6 million for Q1 2026.

  • Quarterly results put Net Income towards Common Stockholders at -$23.6 million for Q1 2026, up 17.09% from a year ago — trailing twelve months through Mar 2026 was -$891000.0 (up 99.07% YoY), and the annual figure for FY2025 was -$5.8 million, up 93.59%.
  • Net Income towards Common Stockholders reached -$23.6 million in Q1 2026 per ELVN's latest filing, down from $68.2 million in the prior quarter.
  • Across five years, Net Income towards Common Stockholders topped out at $68.2 million in Q4 2025 and bottomed at -$28.5 million in Q1 2025.
  • Median Net Income towards Common Stockholders over the past 5 years was -$20.1 million (2025), compared with a mean of -$13.4 million.
  • The largest annual shift saw Net Income towards Common Stockholders crashed 102.73% in 2023 before it skyrocketed 394.29% in 2025.
  • Over 5 years, Net Income towards Common Stockholders stood at -$9.5 million in 2022, then plummeted by 102.73% to -$19.4 million in 2023, then decreased by 19.73% to -$23.2 million in 2024, then surged by 394.29% to $68.2 million in 2025, then plummeted by 134.64% to -$23.6 million in 2026.
  • Business Quant data shows Net Income towards Common Stockholders for ELVN at -$23.6 million in Q1 2026, $68.2 million in Q4 2025, and -$20.1 million in Q3 2025.